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Abstract
Background: Angiotensin converting enzyme (ACE) gene insertion/deletion (I/D) polymorphisms have been
associated with acute coronary syndrome (ACS); however, several controversial results have also been found in
different studied populations. This hospital-based, emergency room, case-control study in Taiwan retrospectively
investigated 111 ACS patients, and 195 non-coronary subjects as a control group, to study the effects of ACE I/D
polymorphism in the most urgent ACS patients. ACE I/D polymorphisms were determined by polymerase chain
reaction-based assays and their associations with ACS risk, severity, and sudden cardiac death were determined.
Results: The ACE DD genotype was associated with ACS incidence. The DD genotype was associated with a
significant 4-fold higher risk of ACS in multivariate analysis (odds ratio (OR) = 4.295; 95% confidence interval (CI):
1.436-12.851, p = 0.009), and a 3.35-fold higher risk of acute myocardial infarction. DD genotype carriers also had
more than 3-fold higher risks of stenosis in all the three coronary arteries, left anterior descending artery infarction,
and anterior wall infarction. In addition, the DD genotype was also associated with a higher risk of sudden cardiac
death (OR = 6.484, 95% CI: 1.036-40.598, p = 0.046).
Conclusions: This study demonstrated that the ACE DD genotype is an independent risk factor for ACS, and in
particular, for acute myocardial infarction. In addition, the ACE DD genotype is also associated with greater ACS
severity and a higher risk of sudden cardiac death. ACE genotyping is recommended for patients with a history of
ACS, and more intensive preventive care is suggested for patients with the DD genotype.
Keywords: Acute coronary syndrome, Angiotensin converting enzyme, Genotype, Pharmacogenomics, Sudden car-
diac death
Background
Acute coronary syndrome (ACS) is a common disease in
the elderly, and a major determinant of morbidity and
mortality in all races, ethnicities, and cultures [1]. The
epidemic of coronary artery disease (CAD), especially its
manifestation as ACS, is a global issue that accounts for
more than 80% of the burden of this disease in develop-
ing countries [2], and results in approximately 30% of
all deaths worldwide each year [3]. The spectrum of
ACS disease severity ranges from unstable angina pec-
toris (UAP) to acute myocardial infarction (AMI),
including ST-segment elevation myocardial infarction
(STEMI) and non-STEMI (NSTEMI). Sudden cardiac
arrest is a major event of heart failure, and sudden car-
diac death frequently presents as the first and only man-
ifestation of previously unrecognized ischemic heart
disease [4]. The prognosis of AMI-related heart failure
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function and morbidity [5]. Clinically, heart failure
usually results in a 20-25% reduction in left ventricular
contractility, and a reduction of more than 40% leads to
cardiogenic shock [6].
Angiotensin converting enzyme (ACE) is a membra-
nous zinc-containing decarboxy-peptidase that catalyzes
the conversion of angiotensin I to angiotensin II and the
inactivation of bradykinin via the kallikrein-kininogen
system [6]. The insertion (I)/deletion (D) polymorphism
in intron 16 of the ACE gene is designated as the pre-
sence or absence of a 287 bp Alu repeat [7,8]. The D
allele is associated with high serum ACE in the order
homozygote deletion (DD) > heterozygote (ID) > homo-
zygote insertion (II) [7,8]. Cardiac ACE activity is also
higher in DD homozygote carriers [9]. Treatment with
ACE inhibitors after MI has been found to attenuate
pathologic left ventricle remodeling, the incidence of
heart failure, and mortality [10,11]. The ACE DD geno-
type or D allele has been associated with MI by increas-
ing the risk of left ventricular enlargement or
remodeling [12] and ischemic or idiopathic dilated car-
diomyopathy [13,14], though there are also several
reports which found no association [15-17]. Genetic
polymorphisms in ACE-related pathways, including the
angiotensin II type 1 receptor (AT1R) and AT2R, have
been associated with MI-related arrhythmias and risk of
sudden cardiac arrest [18]. ACE DD and AT1R 1166 CC
genotypes have been linked with a greater risk of diasto-
lic heart failure [19].
The DD genotype or D allele has been most associated
with increased risk of ACS, ACS severity and cardiovas-
cular death. However, inconsistencies in the clinical sig-
nificance in previous reports suggested that the influence
of the ACE I/D genotypes may differ across the ACS
spectrum. For this reason, we carried out a retrospective
emergency room-based case-control study to evaluate
the association of the ACE I/D polymorphism with the
most urgent ACS events. Therefore, this study addressed
ACE genotypes and ACS incidence, severity, and sudden
cardiac death within the recruited population.
Methods
Subjects
This retrospective case-control study included 111 acute
coronary syndrome (ACS) patients and 195 non-coron-
ary subjects (NCS) who were treated in the emergency
room of Tri-Service General Hospital (TSGH) between
July 2005 and June 2010. The subjects in this study
were all Taiwanese and 20 years of age or older. The
study was approved by the institutional review board.
Clinical and follow-up information were obtained from
the patients’ medical records, and peripheral blood sam-
ples were obtained from the Biobank of TSGH.
Peripheral blood samples of each patient were collected
by the Biobank during the follow-up with informed con-
sent; two of the blood samples of each patient were
used to confirm the ACE genotype. Among the ACS
patients, 91 were identified with ACS by coronary angio-
graphy (defined by > 75% stenosis in any major coron-
ary artery), while 20 ACS patients did not receive
coronary angiography because of their condition [20].
Fifty four ACS patients experienced STEMI, with car-
diac chest pain, serologic evidence of myonecrosis, and
persistent (> 20 min) ST-segment elevation. The other
57 ACS patients had either UAP or NSTEMI, that was
clinically documented as: (1) UAP when cardiac chest
pain was new or worsening without serologic evidence
of myonecrosis (i.e., no elevation of serum troponin or
creatine kinase MB isoenzyme concentration), or
dynamic eletrocardiographic (ECG) changes (i.e., ST
depression and/or T wave inversion); (2) NSTEMI when
the patient had cardiac chest pain and serologic evi-
dence of myocardial necrosis in the absence of ST-seg-
ment elevation on the ECG [21]. The NCS had no
clinical evidence of CAD including: (1) no history of
typical angina pectoris; (2) no abnormal Q wave or ST-
T changes in the resting electrocardiogram; and (3) a
negative Master exercise test. The NCS constituted the
control group and included 135 men and 60 women.
The presence of hypertension, diabetes mellitus,
hypercholesterolemia or smoking was obtained from the
patients’ charts or from the records of examination dur-
ing follow-up medication or hospitalization. In this
study, hypercholesterolemia was defined as a serum
total cholesterol level of 200 mg/dl or more. Diagnosis
of hypertension and diabetes mellitus were performed
according to World Health Organization criteria. A
smoking habit was defined as a daily intake of > 10
cigarettes. Sudden cardiac death was defined as death
within 24 hours of registrati o ni nt h ee m e r g e n c yr o o m ,
and ACS was recorded as the cause of death after failure
of standard cardiac arrest treatment. Other risk factors
were stratified as indicated in each table.
Polymerase chain reaction (PCR) for detection of ACE
Insert/Delete (I/D) polymorphism
Genomic DNA was extracted from peripheral blood
using the Qiagen PureGene DNA Purification Kit
according to the manufacturer’s protocol. The presence
of the I and D alleles of the ACE gene was detected
according to the method in Tiret et al [8]. The sequence
of the sense primer was 5’-CTGGAGACCACTCC-
CATCCTTTCT-3’, and the antisense primer was 5’-
GATGTGGCCATCACATTCGTCAGAT-3’.P C Rw a s
carried out with 80 ng genomic DNA in a final volume
of 50 μl containing 3 mmol/l magnesium chloride, 50
mmol/l potassium chloride, 10 mmol/l Tris-HCl
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μmol of each dNTP and 1 unit Taq-DNA polymerase
(Promega, Madison, WI, USA). Amplification was per-
formed in a DNA thermal cycler 480 (Perkin-Elmer,
Norwalk, CT, USA) involving 1 minute of denaturation
at 94°C, 1 minute of annealing at 55°C and 2 minutes of
extension at 72°C for 35 cycles. In the last cycle, the
extension step was carried out for 10 minutes. There-
after, 10 μl of amplified product was electrophoresed in
a 2% agarose gel containing 0.5 μg/ml of ethidium bro-
mide and was subsequently visually inspected under
ultraviolet light for appropriately sized bands of DNA.
The I allele manifested as a 490 bp band, and the D
allele was seen as a 190 bp band of DNA. Besides, all
DD genotype samples were confirmed using the primers:
forward, 5’-TCGGACCACAGCGCCCGCCACTAC-3’;
and reverse, 5’-TCGCCAGCCCTCCCATGCCCATAA-
3’ with identical PCR conditions except for an annealing
temperature of 67°C, that produced a 335-bp product
only in the presence of the I allele [22].
Data analysis
Patient age at diagnosis was recorded as a continuous
variable and shown as mean ± standard deviation. The
odds ratios (ORs) and corresponding 95% confidence
intervals (CIs) for assessing the effect of the ACE I/D
genotype distribution and allele frequencies on ACS
were calculated by logistic regression analysis with
adjustment for relevant significant variables. All the sta-
tistical analyses were performed using SPSS 16.0 and
Excel 2007. For all statistical tests, p values were two-
sided and the level of significance was set at 0.05.
Results
Risk factors for ACS
Comparisons of the distributions of demographic and
relevant clinical risk factors between ACS patients and
NCS controls and the estimated OR for each risk factor
are listed in Table 1. Patients diagnosed as ACS were
significantly older than control NCS (mean age 64.99 ±
13.85 years and 42.44 ± 11.91 years, respectively). ACS
patients were also more likely to have higher systolic or
diastolic blood pressure and diabetes mellitus than NCS.
T h eg r o u p sw e r es i m i l a rw i t hr e s p e c tt og e n d e ra n d
b o d ym a s si n d e x .I nt h eu n i v a r i a t el o g i s t i cr e g r e s s i o n
model, older age, higher systolic blood pressure or dia-
stolic blood pressure and the presence of diabetes melli-
tus were found to be significant risk factors for ACS.
ACE DD genotype as an independent risk factor for ACS
Table 1 illustrates that ACS patients demonstrated a
lower proportion of II genotypes (33.33%) and ID
Table 1 Univariate and multivariate analyses of ACS risk factors
Subject characteristics ACS
(n = 111)
NCS
(n = 195)
Univariate Multivariate
OR (95%CI) p* OR (95% CI) P*
ACE-genotypes
II 37 78 1 (ref.) 1 (ref.)
ID 51 99 1.086 (0.648-1.821) 0.754 1.284 (0.595-2.773) 0.524
DD 23 18 2.694 (1.298-5.592) 0.008 4.295 (1.436-12.851) 0.009
Demographic factors
Age 64.99 ± 13.85 42.44 ± 11.91 1.127 (1.099-1.156) < 0.001 1.114 (1.082-1.147) < 0.001
Sex -Female 25 60 1 (ref.)
Male 86 135 1.529 (0.892-2.622) 0.123 - -
Clinical risk factors
BMI (kg/m
2) < 27 99 174 1.004 (0.474-2.128) 0.991 - -
≥ 27 12 21
Systolic blood pressure 73 181 1 (ref.) 1 (ref.)
< 140 mmHg
≥ 140 mmHg 38 14 6.730 (3.443-13.156) < 0.001 1.765 (0.525-5.934) 0.358
Diastolic blood pressure 88 179 1 (ref.) 1 (ref.)
< 90 mmHg
≥ 90 mmHg 23 16 2.924 (1.471-5.813) 0.002 1.425 (0.497-4.089) 0.510
Diabetes Mellitus - No 75 187 1 (ref.) 1 (ref.)
Yes 36 8 11.220 (4.983-25.261) < 0.001 2.396 (0.869-6.610) 0.091
On the basis of logistic regression, with statistical significance (p < 0.05) shown in bold ACS: acute coronary syndrome, NCS: non-coronary subjects, BMI: body
mass index
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types (20.72%) than the control population (II, 40.00%;
I D ,5 0 . 7 7 % ;D D ,9 . 2 3 % ) .T h eA C ED Dg e n o t y p ec o n -
ferred a 2.69-fold higher risk of ACS compared with the
II genotype (95% CI: 1.298-5.592, p = 0.008, logistic
regression). After controlling for other risk factors, the
DD genotype was still significantly associated with ACS,
conferring a 4-fold higher risk (OR = 4.295; 95% CI:
1.436-12.851). Age was the only other independent risk
factor under multivariate logistic regression, which was
in accordance with other studies [1,23].
ACE DD genotype associated with ACS type, severity and
mortality
To further evaluate the etiologic effects of ACE I/D poly-
morphisms in ACS, we analyzed the association between
ACE genotypes and different ACS manifestations (UAP
and AMI), complications (hypertension, diabetes melli-
tus, hypercholesterolemia), relevant clinical risk factors
(systolic blood pressure, diastolic blood pressure, total
blood cholesterol and triglyceride and body mass index),
clinical history (heart failure, CAD, MI and family his-
tory) and history of smoking. As shown in Table 2, the
DD genotype conferred a significant 3.35-fold higher risk
of AMI (Table 2, 95% CI: 1.111-10.115, p = 0.032, logistic
regression), however there was no significant association
between ACE I/D polymorphisms and any other risk fac-
tor among the recruited ACS group. A multivariate ana-
lysis was not performed as only ACS was significantly
associated with ACE I/D polymorphisms. The foregoing
results also supported previous studies that the ACE D
allele was associated with higher ACE activity [7-9], con-
verting more angiotensin II and thus stimulating inflam-
matory/fibrogenic responses and scar formation during
myocardial infarction, or inducing reactive oxygen spe-
cies to cause myocardial damage in the border zones and
enlargement of the infarct size [24].
Subsequent analyses evaluated the possible influence
of ACE I/D polymorphisms on final ACS clinical out-
come, and the association between ACE I/D polymorph-
isms and ACS severity and mortality was determined.
Interestingly, ACS patients with the DD genotype had a
significantly higher risk of presenting with a greater
number of stenosed vessels, with a 3.87-fold increased
risk of stenosis in all three coronary arteries (Table 3,
95% CI: 1.085-13.812, p = 0.037, logistic regression). In
addition, the DD genotype was also associated with a
3.08-fold higher risk of left anterior descending artery
infarction (Table 3, 95% CI: 1.041-9.118, p = 0.042), and
a 3.07-fold higher risk of anterior wall infarction (Table
3, 95% CI: 1.039-9.091, p = 0.043). Previous epidemiolo-
gical data showed that an anterior wall myocardial
infarction is usually caused by an occlusion of the left
anterior descending coronary artery [25,26], and the DD
genotype is highly associated with those ACS symptoms.
We also found that the DD genotype was independently
associated with sudden cardiac death (Table 4, OR =
6.484, 95% CI: 1.036-40.598, p = 0.046, logistic regres-
sion). This effect seemed more obvious in AMI patients
(sudden cardiac death in AMI patients: genotype II = 2,
ID = 2, DD = 5; and in UAP patients: genotype II = 0,
ID = 2, DD = 1), but there was no statistical significance
between ACE I/D polymorphism and sudden cardiac
death across the ACS spectrum. A history of heart fail-
ure also conferred a 9.69-fold increased risk of sudden
cardiac death which was similar to that found in pre-
vious epidemiological studies [4,5].
Discussion
The renin-angiotensin system (RAS) has been recog-
nized for many years as a critical pathway for blood
pressure control and kidney function [27]. This 5-year
period emergency room-based study clearly demon-
strates that the ACE DD genotype acts as an indepen-
dent risk factor for ACS requiring emergency treatment
(Table 1), and in particular for AMI (Table 2). In addi-
tion, the ACE DD genotype is also associated with
greater ACS severity, including more stenosed vessels,
greater occlusion of the left anterior descending branch,
and a greater risk of anterior wall myocardial infarction
(Table 3) and also of sudden cardiac death (Table 4).
The ACE DD genotype was reported to be associated
with CAD risk in several studies including ECTIM [7],
INSERM [8], ISIS [10] and CORGENE [28] cohorts, and
subsequent studies revealed that the D allele or DD geno-
type may confer effects mainly on the onset of ACS or
MI [29] by modifying ACE abundance or activity, and
contributing to increases in plaque instability, ulceration
and thrombosis [30]. The ACE D allele was correlated
with an increase in serum or cardiac ACE, thus increas-
ing the conversion of angiotensin I to the peptide precur-
sor angiotensin II which induces aldosterone production
[7-9]. Elevation of circulating aldosterone increases the
risk of arterial hypertension and cardiac fibrosis thus
inducing diastolic dysfunction, ventricular remodeling
and even atherosclerosis [31]. Similar results were also
found in this case-control study, with DD genotype car-
riers having about a four-fold higher risk of ACS than ID
or II genotype carriers. In addition, age of diagnosis, sys-
tolic blood pressure, diastolic blood pressure and diabetes
mellitus were also identified as ACS risk factors in uni-
variate analyses, though only the ACE DD genotype and
age of diagnosis were found to be independent risk fac-
tors. Older age is a well-documented risk factor for CAD
or its manifestation as ACS [1,23], and the ACE DD gen-
otype or D allele had been found in most studies to be a
risk factor for CAD or ACS [12,28,29]. Within the ACS
groups, we also compared disease type, complications,
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Interestingly, only the ACE DD genotype conferred
about 3-fold risk for AMI compared with UAP and this
result was also similar to most studies in different
population or study cohorts [32], although some studies
found no association [14,25]. There was no significance
between any other analyzed risk factor and ACE I/D
polymorphisms; even though DD genotype had been
Table 2 Association between ACE I/D polymorphisms and ACS risk factors
ACE genotypes II (n = 37) ID (n = 51) DD (n = 23)
ACS risk factors Univariate Univariate
n n OR (95%CI) p* n OR (95%CI) p*
ACS spectrum
UAP (n = 57) 22 1 (ref.) 28 7
AMI (n = 54) 15 23 1.205 (0.511-2.839) 0.670 16 3.352 (1.111-10.115) 0.032
Demographic factors
Age (mean) 67.7 ± 11.1 1 (ref.) 64.2 ± 13.5 0.981 (0.949-1.013) 0.232 62.4 ± 18.1 0.972 (0.935-1.010) 0.149
Sex -female 10 1 (ref.) 8 7
male 27 43 2.352 (0.733-7.543) 0.150 16 1.181 (0.375-3.719) 0.776
Complications
Hypertension- No 10 1 (ref.) 20 11
- Yes 27 31 0.574 (0.229-1.437) 0.236 12 0.404 (0.135-1.206) 0.104
Diabetes Mellitus-No 25 1 (ref.) 33 17
- Yes 12 18 0.880 (0.359-2.157) 0.780 6 1.360 (0.427-4.328) 0.603
Hypercholesterolemia-No 31 1 (ref.) 39 19
- Yes 6 12 0.629 (0.212-1.866) 0.403 4 0.919 (0.229-3.684) 0.905
Other clinical risk factors
Systolic blood pressure 22 1 (ref.) 38 13
< 140 mmHg
≥ 140 mmHg 15 13 0.502 (0.202-1.246) 0.137 10 1.128 (0.393-3.236) 0.822
Diastolic blood pressure 27 1 (ref.) 45 16
< 90 mmHg
≥ 90 mmHg 10 6 0.360 (0.118-1.102) 0.074 7 1.181 (0.375-3.719) 0.776
Total cholesterol < 200 mg/dl 31 1 (ref.) 46 17
≥ 200 mg/dl 6 5 0.562 (0.158-2.002) 0.374 6 1.824 (0.509-6.538) 0.356
Triglyceride < 150 mg/dl 34 1(ref.) 42 17
≥ 150 mg/dl 3 9 1.768 (0.500-6.251) 0.377 6 2.912 (0.722-11.736) 0.133
BMI (kg/m
2) < 27 35 1 (ref.) 43 21
≥ 27 2 8 3.256 (0.649-16.328) 0.151 2 1.667 (0.218-12.732) 0.622
History
Heart failure history-No 29 1 (ref.) 41 16
-Yes 8 10 0.884 (0.311-2.512) 0.817 7 1.586 (0.485-5.181) 0.445
CAD history -No 22 1 (ref.) 32 17
-Yes 15 19 0.871 (0.366-2.074) 0.755 6 0.518 (0.166-1.617) 0.257
MI history -No 34 1 (ref.) 46 21
-Yes 3 5 1.232 (0.275-5.512) 0.785 2 1.079 (0.166-7.004) 0.936
Family history of ACS 35 1 (ref.) 50 22
-Yes 2 1 0.350 (0.031-4.012) 0.399 1 0.795 (0.068-9.301) 0.855
Smoking 20 1 (ref.) 29 11
-Yes 17 22 0.892 (0.381-2.091) 0.793 12 1.283 (0.452-3.641) 0.639
On the basis of logistic regression, with statistical significance (p < 0.05) shown in bold. Multivariate analyses were not performed as only the DD genotype was
significantly associated with AMI
ACE, angiotensin converting enzyme, UAP: unstable angina pectoris; AMI: acute myocardial infarction, CAD: coronary artery disease; MI: myocardial infarction.
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diabetes mellitus [34]. Patients with the ACE DD geno-
type appeared to have earlier onset of ACS, with a
younger mean age than ID or II carriers, but there was
no statistical significance among those groups (analysis of
variance p = 0.307).
Although ACE I/D polymorphisms have been compre-
h e n s i v e l ys t u d i e di nC A Do rA C S ,t h e r ea r eo n l yaf e w
studies addressing the clinical significance of ACE geno-
types on the severity of coronary lesions. In this emer-
gency room-based, case-control study, we enrolled the
most urgent ACS cases who required immediate treat-
ment, and we found that DD genotype carriers were
likely to have the most severe ACS, including stenosis in
all three coronary arteries, left anterior descending
artery infarction and also anterior wall infarction (Table
3). Similarly, a previous study found that DD genotype
carriers had a greater number of stenosed arteries and/
or dangerous infarction loci [26].
Finally, we focused this study on the effects of ACE I/
D polymorphisms on sudden cardiac death within 24
hours of the ACS patients being registered in the emer-
gency room. ACE DD genotype carriers also had a
higher mortality risk than ID or II carriers. Genetic
polymorphisms in ACE-related genes have been
associated with risk of MI-related sudden cardiac arrest
[18], and the ACE DD genotype was found to confer an
increased risk of diastolic heart failure [19,33], ACS
recurrence and cardiovascular mortality [19], although
controversial and negative [12,17] results have also been
reported.
Polymorphisms of ACE and its related genes have also
been highly associated with the efficiency of ACE inhibi-
tor treatment and the role of ACE I/D polymorphisms
are particularly well documented [35,36].
Conclusions
In summary, this case-control study has demonstrated
that the ACE DD genotype is an independent risk factor
for ACS incidence, and especially for AMI. In addition,
the ACE DD genotype is associated with greater ACS
severity and greater risk of sudden cardiac death. This
emergency room experience of patients requiring urgent
ACS treatment suggests that ACE DD genotype carriers
should be followed-up and treated especially carefully
because of the higher relative risk of more severe ACS
and sudden cardiac death. Further studies are necessary
to evaluate the personal pharmacogenomic and pharma-
cogenetic effects of ACE I/D polymorphisms to improve
ACS therapeutic strategies and prognosis.
Table 3 Association between ACE I/D polymorphisms and ACS clinical severity
ACE genotypes II (n = 37) ID (n = 51) DD (n = 23)
Clinical symptoms Univariate Univariate
n n OR (95%CI) p* n OR (95%CI) p*
Stenosis numbers
0 or 1 vessel 19 1 (ref.) 20 6
2 vessels 9 12 1.267 (0.435-3.686) 0.665 6 2.006 (0.729-5.515) 0.178
3 vessels 9 19 2.111 (0.530-8.407) 0.289 11 3.870 (1.085-13.812) 0.037
Infarcted artery (yes vs. no)
left anterior descending -No 23 1(ref) 22 8
-Yes 14 29 2.166 (0.912-5.144) 0.080 15 3.080 (1.041-9.118) 0.042
left circumflex -No 21 1(ref) 24 14
-Yes 16 27 1.477 (0.630-3.460) 0.370 9 0.844 (0.292-2.436) 0.753
right coronary -No 17 1(ref) 21 12
-Yes 20 29 1.174 (0.498-2.764) 0.714 11 0.779 (0.275-2.211) 0.639
Infarction locus (yes vs. no)
anterior wall -No 26 1(ref) 39 10
-Yes 11 12 0.727 (0.279-1.893) 0.514 13 3.073 (1.039-9.091) 0.043
inferior wall -No 34 1(ref) 42 19
-Yes 3 9 2.429 (0.609-9.679) 0.208 4 2.386 (0.482-11.803) 0.286
right ventricle myocardial -No 36 1(ref) 48 22
-Yes 1 3 2.250 (0.225-22.533) 0.490 1 1.636 (0.097-27.511) 0.732
others -No 35 1(ref) 50 22
-Yes 2 1 0.350 (0.031-4.012) 0.399 1 0.795 (0.068-9.301) 0.855
* On the basis of logistic regression, with statistical significance (p < 0.05) shown in bold.
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Subject characteristics Survival Expired Univariate Multivariate
(n = 99) (n = 12) OR (95%CI) p* OR (95% CI) p*
ACE-genotypes
II 35 2 1 (ref.) 1 (ref.)
ID 47 4 1.489 (0.258-8.595) 0.656 1.659 (0.264-10.427) 0.589
DD 17 6 6.176 (1.126-33.876) 0.036 6.484 (1.036-40.598) 0.046
ACS spectrum
UAP (n = 57) 54 3 1 (ref.)
AMI (n = 54) 45 9 3.600 (0.919-14.100) 0.066
Demographic factors
Age 65.02 ± 13.40 64.85 ± 17.90 0.999 (0.956-1.043) 0.949 - -
Sex -Female 21 4 1 (ref.)
Male 78 8 1.857 (0.510-6.769) 0.348 - -
Complications
Hypertension- No 36 5 1 (ref.) - -
- Yes 63 7 0.800 (0.237-2.706) 0.720
Diabetes Mellitus-No 68 7 1 (ref.) - -
- Yes 31 5 1.567 (0.461-5.327) 0.472
Hypercholesterolemia-No 78 11 - -
- Yes 21 1 0.338 (0.041-2.766) 0.312
Other clinical risk factors
Systolic blood pressure 67 6 1(ref.) - -
< 140 mmHg
≥ 140 mmHg 32 6 2.094 (0.626-7.003) 0.230
Diastolic blood pressure 78 10 1 (ref.) - -
< 90 mmHg
≥ 90 mmHg 21 2 0.743 (0.151-3.653) 0.715
Total cholesterol 83 11 1 (ref.) - -
< 200 mg/dl
≥ 200 mg/dl 16 1 0.472 (0.057-3.913) 0.486
Triglyceride < 150 mg/dl 81 11 1 (ref.) - -
≥ 150 mg/dl 18 1 0.409 (0.050-3.374) 0.406
BMI (kg/m
2) < 27 88 11 1 (ref.) - -
≥ 27 11 1 0.727 (0.085-6.187) 0.771
History
Heart failure history-No 82 4 1 (ref.)
-Yes 17 8 9.647 (2.606-35.716) 0.001 9.698 (2.468-38.106) 0.001
CAD history -No 63 8 1 (ref.) - -
-Yes 36 4 0.875 (0.246-3.110) 0.836
MI history -No 91 10 1 (ref.) - -
-Yes 8 2 2.275 (0.423-12.224) 0.338
Family history of ACS 96 11 1 (ref.) - -
-Yes 3 1 2.909 (0.278-30.430) 0.373
Smoking 53 7 1 (ref.) - -
-Yes 46 5 0.823 (0.245-2.770) 0.753
*On the basis of logistic regression, with statistical significance (p < 0.05) shown in bold.
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